The big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.
Belgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications.
Sanofi further launches into the messenger RNA space with US$3.2bn buy-out of mRNA pioneer Translate Bio.
Life sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Cancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Italian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
Mainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.